Origins, Development, Current Challenges and Future Directions with Activated Prothrombin Complex Concentrate for the Treatment of Patients with Congenital Haemophilia with Inhibitors

Congenital haemophilia A (HA) is caused by deficiency of coagulation factor VIII (FVIII) activity, leading to spontaneous or traumatic bleeding events. While FVIII replacement therapy can treat and prevent bleeds, approximately 30% of patients with severe HA develop inhibitor antibodies that render...

Descripción completa

Detalles Bibliográficos
Autores principales: Brackmann, Hans H., Schramm, Wolfgang, Oldenburg, Johannes, Cano, Viridiana, Turecek, Peter L., Négrier, Claude
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Georg Thieme Verlag KG 2020
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772007/
https://www.ncbi.nlm.nih.gov/pubmed/32717751
http://dx.doi.org/10.1055/a-1159-4273

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772007/
https://www.ncbi.nlm.nih.gov/pubmed/32717751
http://dx.doi.org/10.1055/a-1159-4273

Ejemplares similares